Background This study aimed to describe a case of rhabdomyolysis and acute kidney injury
potentiated by a drug-drug interaction (DDI) between cyclosporine, leflunomide, and …

Background The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors lovastatin
and simvastatin have been associated with rhabdomyolysis in cardiac transplant recipients …

Background: Cardiovascular disease is the most common cause of morbidity and mortality
among long-term renal transplant recipients, and hyperlipidemia is an important risk factor …

Statin-induced rhabdomyolysis is a frequent complication in renal transplant recipients
receiving cyclosporine, but incidences are different between different types of statins. Statins …

The HMGCoA reductase inhibitors, lovastatin (L) and simvastatin (S), have been associated
with rhabdomyolysis in cardiac transplant recipients. L, S, and cyclosporine (CY) are all …

The immunosuppressive drug cyclosporin A [1] and the cholesterol-lowering drug
simvastatin [2] are both known to induce rhabdomyolysis rarely. Their combination …

Rhabdomyolysis, a syndrome characterized by muscle necrosis with release of toxic
intracellular muscle constituents, can be a potentially fatal side effect of medical therapy. It …

Objective To discuss the pathogenesis of the statin-induced rhabdomyolysis in renal
transplant recipients. Methods We presented two renal transplant recipients who developed …

We read with interest Phanish et al's (1) letter on colchicine-induced rhabdomyolysis. Their
patient, a renal allograft recipient, developed rhabdomyolysis 2 months after initiating …

Dear Sir, Post-transplant hyperlipidemia (PTHL) is a frequent metabolic disease following
renal grafting, and atherosclerotic vascular disease represents a major burden to transplant …